We demonstrated that co-targeting IGF-1R and downstream pathways (AMPK & IGF-1R, mTOR & IGF-1R, and AMPK & Akt) led to synergistic growth inhibition in ALL cell models. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.